SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

Stopped early · Phase 2

Conditions studied: Coronary Artery Disease, Atherosclerosis, Stent Placement

In brief

The purpose of this study is to see if one month of dual antiplatelet therapy (DAPT) combined with the placement of the Synergy® Stent with IVUS (intravascular ultrasound) is safe for patients who are at high risk of bleeding (HBR).

Key facts

Study ID

NCT03606642

Run by

HonorHealth Research Institute

People needed

50

Starts

2018-11-19

Expected to finish

2022-08-08

Last updated by the study team

2024-12-27

Who can join

Age: 75 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is considered at high risk for bleeding, defined as meeting one or more of the following criteria at the time of enrollment:
• Greater than or equal to 75 years of age and, in the opinion of the investigator, the risk of bleeding associated with >1 months of DAPT outweighs the benefit,
• need for chronic or lifelong anticoagulation therapy
• history of major bleeding (severe/life threatening or moderate bleeding based on the GUSTO classification) within 12 months of the index procedure,
• history of stroke (ischemic or hemorrhagic),
• renal insufficiency (creatinine ≥2.0 mg/dl) or failure (dialysis dependent),
• platelet count ≥20,000/μLto ≤100,000/μL (microliters)
• In the opinion of investigator, patient is at significant risk of falling
• Patient abuses drugs or alcohol
• Hemoglobin ≤11.0 u/dl 2. Subject must be 18 years of age 3. Subject must be able to take study required dual antiplatelet therapy (1 month of P2Y12 inhibitor and aspirin, 13 months of antiplatelet monotherapy) 4. Subject is willing to comply with all protocol requirements, including agreement to stop taking P2Y12 inhibitor at the 1-month milestone if eligible per protocol 5. Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific procedures are performed
• Angiographic Inclusion Criteria:
• Subject must have had implantation of at least one Synergy Stent and the use of Boston Scientific IVUS for guided stent implantation
• All implanted stents must be post dilated and must meet the following IVUS success criteria:
• treated lesions in which the stent cross sectional area exceeds the distal reference cross sectional area
• if the stent cross sectional area is less than the distal reference cross sectional area additional post-dilatation must be performed, followed by IVUS
• above IVUS criteria must be met after the 2nd post dilatation NOTE: if the IVUS criteria is not met after the 2 post dilatation the patient is excluded
• Stent procedure performed by an approved investigator
• Vessel diameter ≥ 2.25 mm and ≤4.0 mm and lesion length ≤34mm
• Pre-dilatation is up to the discretion of the investigator

You may not qualify if…

• Subject with an indication for the index procedure of acute ST elevation MI (STEMI)
• Subject with an indication for the index procedure of Non ST elevation MI (NSTEMI), based on the 3rd Universal MI definition
• Subject with treatment with another coronary stent, other than SYNERGY Stent during the index procedure
• Subject with a planned staged procedure >7 days following the index procedure. (Note: Planned staged procedures are allowed if performed within 7 days of the index procedure and only when SYNERGY stents are used for both the index and staged procedure). Discontinuation of DAPT should occur 1 month after the last PCI procedure is completed.
• A staged procedure cannot in a 3rd epicardial vessel if 2 epicardial vessels were treated during the index procedure
• Subject has a known allergy to: contrast (that cannot be adequately pre-medicated), the SYNERGY Stent system or protocol-required concomitant medications (e.g., everolimus or structurally related compounds, polymer or individual components, all P2Y12 inhibitors and aspirin)
• Subject previously treated at any time with intravascular brachytherapy
• Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding
• Subject is participating in an investigational drug or device clinical trial that has not reached its primary endpoint (Note: registry, observational, data collection studies are not exclusionary)
• Subject intends to participate in an investigational drug or device clinical trial within 12 months following the index procedure (Note: registry, observational, data collection studies are not exclusionary)
• Subject is judged inappropriate for discontinuation from P2Y12 inhibitor use at 1 month, due to another condition requiring chronic P2Y12 inhibitor use
• if at the 30 day visit, the patient has had a peri-procedural NSTEMI with an enzyme elevation >5% of the upper 99th percentile of either creatine kinase-myocardial band (CK-MB) or Troponin, the patient should not be taken off DAPT
• Subject with planned surgery or procedure necessitating discontinuation of P2Y12 inhibitor within 1 month following index procedure
• Subject is a woman who is pregnant or nursing
• Subject with a current medical condition with a life expectancy of less than 12 months
• Subject with implantation of a drug-eluting stent other than SYNERGY Stent within 11 months prior to index procedure
• Have been previously consented for this trial and screen failed
• Any other clinically significant comorbidities, which in the judgement of the investigator, could compromise compliance with the protocol, interfere with interpretation of the study results, or predispose the patient to safety risks.
• Angiographic Exclusion Criteria:
• Target lesion(s) is located within a saphenous vein graft or an arterial graft
• TIMI (Thrombolysis In Myocardial Infarction) flow 0 (total occlusion)
• Target lesion(s) is located in the left main
• Potential Target lesion(s) that involve a complex bifurcation (i.e. bifurcation lesion requiring treatment with more than one stent)
• Thrombus, or possible thrombus, present in the target vessel (by visual estimate)
• Patients requiring a treatment of more than two native epicardial vessels

Where it is running

• HonorHealth Research Institute — Scottsdale, Arizona, United States
• Massachusetts General Hospital, Corrigan Minehan Heart Center — Boston, Massachusetts, United States
• Northwell Hospital Systems — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.